Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Trial Profile

Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Eosinophilia; Nasal polyps; Sinusitis
  • Focus Therapeutic Use
  • Sponsors Knopp Biosciences
  • Most Recent Events

    • 07 Mar 2017 According to a Knopp Biosciences media release, results from this study were presented at 2017 American Academy of Allergy and Immunology (AAAAI).
    • 07 Mar 2017 Results published in the Knopp Biosciences media release.
    • 06 Mar 2017 Results (n=11) presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top